Abstract:Purpose: The combination of vancomycin and piperacillin/tazobactam (VAN + PTZ) provides a broad spectrum of activity against multiple pathogens. However, a major issue in previous research concerned significant nephrotoxicity associated with this drug combination, and most studies have been conducted in American and European countries, with no similar data available from China. Therefore, this study evaluated the nephrotoxic effects of VAN + PTZ in a large-scale Chinese cohort to determine the prevalence of acute kidney injury (AKI) in this population by comparing PTZ and vancomycin monotherapies and the combined use of vancomycin and beta-lactam antibiotics. Methods: This retrospective cohort study identified adult patients who received vancomycin either as monotherapy or in combination with PTZ or car-bapenem (VAN + CAR) for at least 48 hours at Jiangsu Province Hospital from January 1, 2017, to December 31, 2018. Patients were also evaluated for the development of AKI, defined according to the Kidney Disease Improving Global Outcome criteria. Duration of vancomycin exposure, steady-state trough vancomycin concentrations, and other risk factors for AKI were assessed. A Bayesian network metaanalysis was conducted to validate our results and comparatively evaluate the nephrotoxicity of beta-lactam antibiotics in combination with vancomycin. Findings: In all, 752 patients were included in the present study. The prevalence of AKI was higher in the VAN + PTZ group than in the VAN and VAN + CAR groups (15.2% vs 4.0% and 6.0%, respectively). After adjustment for confounding factors, VAN + PTZ was still related to AKI (odds ratio [OR] = 4.37; 95% CI, 1.65-11.59; P = 0.003). The network meta-analysis indicated that VAN + PTZ was associated with a significantly higher risk for AKI than was VAN (OR = 3.23; 95% CI, 2.50-4.35), PTZ (OR = 2.86; 95% CI, 1.924.12), VAN + cefepime (FEP) (OR = 2.37; 95% CI, 1.80-3.19), or VAN + CAR (OR = 2.28; 95% CI, 1.64-3.21). However, there was no significant difference with respect to AKI prevalence among the VAN, PTZ, VAN + FEP, and VAN + CAR groups. (C) 2021 Elsevier Inc.

Analysis of Adverse Drug Reactions Caused by Vancomycin and Norvancomycin

The study on adverse reactions induced by vancomycin or norvancomycin

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

[The Adverse Reactions of Parenteral Norvancomycin in 1031 Patients].

Analysis of the Adverse Drug Reactions Reports of 139 Cases

Analysis on Adverse Drug Reactions in Our Hospital from 2008 to 2010

Analysis of Adverse Drug Reactions in 468 Cases

Analysis on 522 cases of antibacterial-related adverse drug reaction/event reports

Analysis of 281 Adverse Drug Reaction Reports of Antineoplastics Drugs in Our Hospital

Analysis of 114 Severe ADR Cases Induced by Antibacterial Drugs in Our Hospital

Analysis of Adverse Drug Reaction of NSAIDs Reported in Domestic Medical Journals Within Past 43 Years

2008-2011 Adverse Drug Reaction Analysis of 490 Cases in Huadong Hospital

Comparative Prevalence of Acute Kidney Injury in Chinese Patients Receiving Vancomycin with Concurrent -Lactam Antibiotics: A Retrospective Cohort Study

Analysis on Rationality of Vancomysin Use in Our Hospital

Safety profiles of vancomycin in pediatrics based on China hospital pharmacovigilance system: A retrospective cohort study

Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis

Analysis on 428 Cases Adverse Drug Reaction/event Reports of Antibacterial Agents

Analysis of 187 Cases of Adverse Reactions Caused by Anti-Infection Drugs in Our Hospital

Analysis on 342 Repors and Discssion about the Methods of Prevention with Adverse Drug Reactions/events

The Necessity of Therapeutic Drug Monitoring of Vancomycin in Clinical Use: A Systematic Review

Retrospective Analysis of the Use of Vancomycin Therapy in the Treatment of Infection Diseases